BioAtla (BCAB) Cash from Financing Activities (2020 - 2026)
BioAtla (BCAB) posted quarterly Cash from Financing Activities of $110000.0 for Q1 2026, up 127.85% year-over-year from $48277.8 in Q1 2025, and down 98.36% quarter-over-quarter from $6.7 million in Q4 2025.
BioAtla (BCAB) Cash from Financing Activities (2020 - 2026) Analysis & Trends
BioAtla's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $110000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 127.85% year-over-year to $110000.0; the TTM figure through Mar 2026 stood at $6.8 million (down 25.72% YoY), while the FY2025 annual figure was $6.3 million, down 34.01% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $110000.0, down from $6.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $61.8 million in Q4 2022, with the low at -$405000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is -$13000.0 (2024), against an average of $4.5 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 7726.05% in 2024, then plunged 2938.46% in 2025.
- BioAtla's Cash from Financing Activities stood at $61.8 million in 2022, then slumped by 99.81% to $119000.0 in 2023, then surged by 7726.05% to $9.3 million in 2024, then dropped by 27.92% to $6.7 million in 2025, then plunged by 98.36% to $110000.0 in 2026.
- Business Quant data shows BCAB's Cash from Financing Activities at $110000.0 in Q1 2026, $6.7 million in Q4 2025, and -$6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 6.71 Mn |
| Dec 31, 2025 | 6.71 Mn |
| Sep 30, 2025 | -6,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | 9.31 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Mar 31, 2024 | -13,000.00 |